Niosomes: a review of their structure, properties, methods of preparation, and medical applications

Yeo, Pei Ling; Lim, Chooi Ling; Chye, Soi Moi; Ling, Anna Pick Kiong; Koh, Rhun Yian

doi:10.1515/abm-2018-0002

Cited by 105 publications

(42 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Niosomal formulations of antimicrobial agents represent a promising tool for enhancement of their activity. 32 Two ciprofloxacin-loaded niosomal preparations were tested; preparation II had an enhanced antimicrobial activity against ciprofloxacin resistant clinical isolates compared to preparation I. Encapsulation of ciprofloxacin, in niosomal preparation II, reduced its MIC by 8-32-fold in most isolates, and caused reversal of resistance phenotype in three isolates. A previous study by Satish et al 13 has recorded a reduction of only 2-4-fold in ciprofloxacin MIC, by niosomal formulations tested on ciprofloxacin resistant isolates.…”

Section: Discussionmentioning

confidence: 99%

The Antimicrobial Activity of Ciprofloxacin-Loaded Niosomes against Ciprofloxacin-Resistant and Biofilm-Forming Staphylococcus aureus

Kashef

Saleh

Assar

et al. 2020

IDR

View full text Add to dashboard Cite

The threat of Staphylococcus aureus antimicrobial resistance is increasing worldwide. Niosomes are a new drug delivery system that enhances the antimicrobial potential of antibiotics. We hereby aim to evaluate the antimicrobial and antibiofilm activity of ciprofloxacin-loaded niosomes. Methods: The antimicrobial susceptibility of clinical S. aureus isolates (n=59) was determined by Kirby-Bauer disk diffusion method. Their biofilm formation activity was tested by Christensen's method. Two ciprofloxacin-loaded niosomal formulations were prepared by thin-film hydration method, and their minimum inhibitory concentrations (MIC) were determined by agar dilution method, against ciprofloxacin-resistant and biofilm-forming isolates (n=24). Their ability to inhibit biofilm formation and eradicate already formed biofilms was evaluated and further confirmed by scanning electron microscope images. Non-synonymous mutations, in a quinolone resistance-determining regions of S. aureus isolates, were detected by polymerase chain reaction. Results: Most of the isolates were methicillin-(47/59) and ciprofloxacin-resistant (45/59). All except two isolates were capable of biofilm production. Niosomal preparation I reduced ciprofloxacin MIC by twofold in four isolates, whereas preparation II reduced ciprofloxacin MIC of most isolates by 8-to 32-fold, with three isolates that became ciprofloxacinsusceptible. Non-synonymous mutations were detected in isolates that maintained phenotypic ciprofloxacin resistance against ciprofloxacin-loaded niosomal preparation II. Ciprofloxacinloaded niosomes reduced the minimum biofilm inhibitory concentration and the minimum biofilm eradication concentration in 58% and 62% of the tested isolates, respectively. Conclusion: Ciprofloxacin-loaded niosomes can restore ciprofloxacin activity against resistant S. aureus isolates. To our knowledge, this is the first report on the inhibition of biofilm formation and eradication of formed biofilms by ciprofloxacin-loaded niosomes.

show abstract

Section: Discussionmentioning

confidence: 99%

The Antimicrobial Activity of Ciprofloxacin-Loaded Niosomes against Ciprofloxacin-Resistant and Biofilm-Forming Staphylococcus aureus

Kashef

Saleh

Assar

et al. 2020

IDR

View full text Add to dashboard Cite

show abstract

“…The negative charge inductors such as dicetyl, dihexadecyl phosphate, and lipoamino acid and positive charge inductors such as stearylamine and cetylpyridinium chloride help to stabilize and enhance the bioadhesion of vesicles at the surface of biological membranes, increasing the bioavailability of biocomponents (Yeo, Lim, Chye, Ling, & Koh, 2017). By the adsorption of high molecular weight compounds such as chitosan derivatives, polyoxyethylene derivatives, and antibodies onto the liposomal surface, the sterically stabilized liposomes, so‐called “stealth liposomes,” are obtained.…”

Section: Role Of the Nanocarriers In Improving Nutraceutical Bioavailmentioning

confidence: 99%

Bioavailability of nutraceuticals: Role of the food matrix, processing conditions, the gastrointestinal tract, and nanodelivery systems

Dima

Assadpour

Dima

et al. 2020

Comp Rev Food Sci Food Safe

170

View full text Add to dashboard Cite

Nowadays, many consumers prefer foods with a high content of nutraceuticals that contribute to the prevention or healing of chronic diseases. Therefore, in recent years, more and more researchers have studied the bioefficiency, safety, and toxicity of nutraceutical-enriched foods. The key stage of nutraceutical bioefficiency is oral bioavailability, which involves the following processes: the release of nutraceuticals from food matrices or nanocarriers in gastrointestinal fluids, the solubilization of nutraceuticals and their interaction with other components of gastrointestinal fluids, the absorption of nutraceuticals by the epithelial layer, and the chemical and biochemical transformations into epithelial cells. These processes are endogenous factors that greatly influence the bioavailability of nutraceuticals. In addition to endogenous factors, the bioavailability of nutraceuticals is also affected by exogenous factors, such as: physicochemical properties of nutraceuticals, food matrix, food processing and storage, and so forth. Both the endogenous and exogenous factors are comprehensively analyzed in this review. Thus, the physicochemical and enzymatic processes involved in food digestion are described, highlighting the role of each stage of gastrointestinal tract (mouth, stomach, and intestine) in nutraceuticals bioaccessibility. The structure and functions of the mucus and epithelial layers, the mechanisms involved in the active and passive transport of nutraceuticals through the cell membrane, and phase I and phase II metabolism reactions are also discussed. Finally, this review focuses on several types of bioactive-loaded nanocarriers such as lipid-based, surfactant-based, and biopolymeric nanocarriers that improve the bioavailability of nutraceuticals. K E Y W O R D Sbioaccessibility, bioavailability, food matrix, gastrointestinal fate, nanocarriers, nutraceuticals 954

show abstract

“…Therefore, it is not surprising that niosomes (as nanocarrier) are currently being used to deliver drugs such as (i) 5-Fluorouracil, increasing drug penetration in skin cancer treatment; (ii) tamoxifen citrate, providing higher cytotoxicity against breast cancer cells; and (iii) curcumin, giving more significant apoptotic effect towards ovarian cancer cells [20]. However, there is no study which has been conducted on dual drug usage (Cis and Gem) to treat lung cancer via aerosolization.…”

Section: Introductionmentioning

confidence: 99%

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

et al. 2021

View full text Add to dashboard Cite

Gemcitabine (Gem) and cisplatin (Cis) are currently being used for lung cancer treatment, but they are highly toxic in high dosages. This research aimed to develop a niosome formulation containing a low-dosage Gem and Cis (NGC), as an alternative formulation for lung cancer treatment. NGC was prepared using a very simple heating method and was further optimized by D-optimal mixture design. The optimum NGC formulation with particle size, polydispersity index (PDI), and zeta potential of 166.45 nm, 0.16, and −15.28 mV, respectively, was obtained and remained stable at 27 °C with no phase separation for up to 90 days. The aerosol output was 96.22%, which indicates its suitability as aerosolized formulation. An in vitro drug release study using the dialysis bag diffusion technique showed controlled release for both drugs up to 24 h penetration. A cytotoxicity study against normal lung (MRC5) and lung cancer (A549) cell lines was investigated. The results showed that the optimized NGC had reduced cytotoxicity effects against both MRC5 and A549 when compared with the control (Gem + Cis alone) from very toxic (IC50 < 1.56 µg/mL) to weakly toxic (IC50 280.00 µg/mL) and moderately toxic (IC50 = 46.00 µg/mL), respectively, after 72 h of treatment. These findings revealed that the optimized NGC has excellent potential and is a promising prospect in aerosolized delivery systems to treat lung cancer that warrants further investigation.

show abstract

Niosomes: a review of their structure, properties, methods of preparation, and medical applications

Cited by 105 publications

References 100 publications

<p>The Antimicrobial Activity of Ciprofloxacin-Loaded Niosomes against Ciprofloxacin-Resistant and Biofilm-Forming <em>Staphylococcus aureus</em></p>

<p>The Antimicrobial Activity of Ciprofloxacin-Loaded Niosomes against Ciprofloxacin-Resistant and Biofilm-Forming <em>Staphylococcus aureus</em></p>

Bioavailability of nutraceuticals: Role of the food matrix, processing conditions, the gastrointestinal tract, and nanodelivery systems

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

Contact Info

Product

Resources

About